Delivra Health Brands Inc.
Navigating Tariffs via Diversified Manufacturing & Geographic Expansion
Published: 5/30/2025
Author: FRC Analysts

Sector: Healthcare | Industry: Drug Manufacturers-Specialty & Generic
Ticker Symbols:DHBUF - NASDAQ 🔹DHB.V - TSX 🔹
Rating and Key Data
Metrics | Value |
---|---|
Current Price | CAD $0.24 |
Fair Value | CAD $0.72 |
Risk | 3 |
52 Week Range | CAD $0.11-0.45 |
Shares O/S (M) | 31 |
Market Cap. (M) | CAD $8 |
Current Yield (%) | N/A |
P/E (forward) | N/A |
P/B | 1.8 |
Already a subscriber?
Want to know the fair value of the stock?
Subscribe for free to get exclusive insights and data.
Report Highlights
- DHB is up 50% since our previous report in March 2025, outperforming the S&P Personal Care Index, which rose 1%.
- Q3-FY2025 (ended March 2025) revenue grew 1% YoY, in line with our estimate. Management remains confident in achieving YoY revenue growth this year, following four consecutive years of growth: 2% in FY2021 and FY2022, 20% in FY2023, and 26% in FY2024.
- Trump’s tariffs have little direct impact on DHB due to its use of manufacturing sites in both Canada and the U.S. However, there is a risk of a tariff-induced recession or economic slowdown, which could impact consumer spending on personal care products. Recent trade agreements with the U.K., and a temporary deal with China, coupled with a trade court ruling against Trump's tariffs (though temporarily nullified by appeal), suggest that Trump is likely to reverse or soften many of his administration's initial measures.
- DHB’s products are available at 30k+ distribution points, including established retail/pharmacy chains such as Shoppers Drug Mart, Walmart (NYSE: WMT), and Kroger (NYSE: KR). DHB